📰 Michael Yee News
Page 39 - Michael Yee News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Yee. Real-time updates on events, politics, business and more.
October 1, 2021
An interim analysis of data from 775 patients in the Phase III portion of the MOVe-OUT trial showed that 28 of 385 patients (7.3%) who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 53 of 377 patients (14.1%) treated with placebo.
October 1, 2021
Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.
October 1, 2021
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe…
October 1, 2021
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
October 1, 2021
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe…
October 1, 2021
-An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that...
October 1, 2021
HEALTH-CORONAVIRUS/MERCK-TREATMENT (UPDATE 4, PIX):UPDATE 4-Merck pill seen as huge advance, raises hope of preventing COVID-19 deaths
October 1, 2021
A pill developed by U.S. drugmaker Merck could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, with…
October 1, 2021
Merck & Co., said today it will pursue FDA emergency use authorization (EUA) “as soon as possible” for molnupiravir, the COVID-19 oral antiviral candidate it is developing with Ridgeback Biotherapeutics, following Phase III data showing an approximately 50% reduction in the risk of hospitalization or death in patients 29 days after treatment with the pill.
October 1, 2021
If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19